MNA-D for cSCC

STUDY BASICS

Do you have a diagnosis of Cutaneous Squamous Cell Carcinoma (cSCC)? You may be eligible for a research study to test a new method of experimental treatment for cSCC using small adhesive-like patches (a micro-needle array or MNA for short), which is loaded with doxorubicin, a chemotherapy agent.

STUDY PURPOSE

The purpose of this study is to test a new method of experimental treatment for Cutaneous Squamous Cell Carcinoma (cSCC) using small adhesive-like patches (a micro-needle array or MNA for short), which is loaded with doxorubicin, a chemotherapy agent. These patches look like Velcro and have pointy ends of microscopic size. After sticking on the skin, tiny prickles bring the drug into the cSCC lesion. Although doxorubicin is FDA approved for some uses, these patches are considered experimental and are not yet approved by the Food and Drug Administration (FDA) for use in humans.

COULD THIS STUDY BE RIGHT FOR YOU?

• 18 years of age or older
• diagnosed with Squamous Cell skin cancer

WHAT PARTICIPANTS CAN EXPECT

Study procedures occur during the screening, on-study, and follow-up phases. These procedures include a history and physical exam, cardiogram, blood work to test liver and kidney function, research blood samples, placement of the study drug micro-needle array patch (MNA-D) on your Cutaneous Squamous Cell Carcinoma (cSCC) at four consecutive weekly visits, assessments of your cSCC by visual inspection and photographs, monitoring for side effects and medications, two research skin biopsies and a standard of care full excision of your cSCC at the final follow up visit.